To build a prognostic score model containing indispensible tumour markers for metastatic nasopharyngeal carcinoma in an epidemic area

被引:58
作者
Jin, Y.
Cai, X. Y.
Cai, Y. C.
Cao, Y.
Xia, Q.
Tan, Y. T.
Jiang, W. Q.
Shi, Y. X. [1 ]
机构
[1] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol S China, Guangzhou 510060, Guangdong, Peoples R China
关键词
Circulating tumour markers; Metastatic nasopharyngeal carcinoma; Prognostic factors; Prognostic score model; UNDIFFERENTIATED CARCINOMA; ALKALINE-PHOSPHATASE; DISTANT METASTASES; VIRUS-DNA; PLASMA; EBV; CANCER; BONE;
D O I
10.1016/j.ejca.2011.09.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and objective: The survival outcomes of patients with metastatic nasopharyngeal carcinoma (NPC) differ significantly between individuals. The aim of this study is to build a prognostic score model (PSM) incorporating circulating tumour markers for metastatic NPC in an epidemic area. Methods: Seven hundred and ninety-nine patients with disseminated NPC were analysed retrospectively. Univariate and multivariable analyses were conducted using the Cox proportion hazards model. Factors analysed included patients, characteristics (gender, age group, performance status), circulating tumour-marker characteristics (Epstein-Barr virus (EBV) DNA level, EBV VCA-IgA level, lactate dehydrogenase (LDH) level, alkaline phosphatase (ALP) level), basic laboratory characteristics (leucocyte count, haemoglobin level, albumin level), and disease characteristics (presence of metastasis at presentation, disease-free interval, number of metastatic sites, specific metastatic sites). The PSM was built according to numerical score derived from the regression coefficients of each independent prognostic variable. The prognostic score of each patient was calculated by totalling up the scores of each independent variable. Results: Independent prognostic factors included performance status, age, haemoglobin level, LDH level, ALP level and EBV DNA level. Three prognostic groups based on PSM were obtained: low risk (total score = 0-4); intermediate risk (5-8); high risk (9-12). Median survivals of the three groups were 25.5, 15.1 and 7 months, respectively, (P < 0.001). Conclusion: Clinical and laboratory characteristics can help guide the prognostication of patients with metastatic NPC in epidemic areas. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:882 / 888
页数:7
相关论文
共 30 条
  • [1] AN X, 2011, CANCER
  • [2] [Anonymous], UROL ONCOL
  • [3] Treatment for metastatic nasopharyngeal carcinoma
    Bensouda, Y.
    Kaikani, W.
    Ahbeddou, N.
    Rahhali, R.
    Jabri, M.
    Mrabti, H.
    Boussen, H.
    Errihani, H.
    [J]. EUROPEAN ANNALS OF OTORHINOLARYNGOLOGY-HEAD AND NECK DISEASES, 2011, 128 (02) : 79 - 85
  • [4] The enigmatic epidemiology of nasopharyngeal carcinoma
    Chang, Ellen T.
    Adami, Hans-Olov
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2006, 15 (10) : 1765 - 1777
  • [5] Distant metastases from nasopharyngeal cancer
    Chiesa, F
    De Paoli, F
    [J]. ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY AND ITS RELATED SPECIALTIES, 2001, 63 (04): : 214 - 216
  • [6] Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type
    Fandi, A
    Bachouchi, M
    Azli, N
    Taamma, A
    Boussen, H
    Wibault, P
    Eschwege, F
    Armand, JP
    Simon, J
    Cvitkovic, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (06) : 1324 - 1330
  • [7] Gunn GB, 2004, J NEURO-ONCOL, V68, P87
  • [8] Lung metastasis alone in nasopharyngeal carcinoma: A relatively favorable prognostic group - A study by the Hong Kong nasophatyngeal carcinoma study group
    Hui, EP
    Leung, SF
    Au, JSK
    Zee, B
    Tung, S
    Chua, D
    Sze, WM
    Law, CK
    Leung, TW
    Chan, ATC
    [J]. CANCER, 2004, 101 (02) : 300 - 306
  • [9] LEUNG SF, 1991, J OTOLARYNGOL, V20, P27
  • [10] Prognostic factors affecting the outcome of nasopharyngeal carcinoma
    Liu, MT
    Hsieh, CY
    Chang, TH
    Lin, JP
    Huang, CC
    Wang, AY
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2003, 33 (10) : 501 - 508